Cart is empty The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment, reports a new study.
The majority of patients with metastatic colorectal cancer whose cancer did not progress during initial treatment with immune checkpoint inhibitors (ICIs) had no disease progression two years after discontinuing treatment, reports a new study.
Leave A Comment